In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors [expression data]

Mice were given B16F10 (melanoma) tumors on the left and right flank. Anti-CD40 agonist and MPL were given directly into the right tumor along with systemic anti-PD1 administration. Treatment resulted in potent regression of the treated (i.e. right) tumor as well as the distant (i.e. left) tumor. We used microarray analysis to examine global gene expression changes in response to therapy. Mice bearing tumors were treated with: (1) isotype control (2) anti-PD1 alone and (5) anti-CD40, MPL, and anti-PD1 triple combination (called CMP). From each mouse, the distant tumors were harvested at 1 week after start of treatment.